Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Cisco Systems Inc. (NASDAQ: CSCO) beat Q2 expectations but offered a weak outlook.
• Clear Channel Communications Inc. (NYSE: CCU) higher Q1 profits failed to beat expectations.
• Crocs Inc. (NASDAQ: CROX) just missed EPS estimates but raised its full-year guidance.
• CVS Caremark Corp. (NYSE: CVS) strong Q1 results only met Wall Street expectations.
• eResearch Technology Inc. (NASDAQ: ERES) beat Q1 expectations and offered Q2 and full-year guidance.
• Foster Wheeler Ltd. (NASDAQ: FWLT) beat estimates due to a boost in its power plant segment.
• Internet Brands Inc. (NASDAQ: INET) reported strong Q1 results on ongoing M&A.
• Midway Games Inc. (NYSE: MWY) widened its loss in Q1 but beat expectations.
• News Corp. (NYSE: NWS) Q3 earnings jumped on a one-time transaction with Liberty Media.
• NVIDIA Corp. (NASDAQ: NVDA) missed Q1 estimates but was upgraded by analysts anyway.
• NYSE Euronext (NYSE: NYX) reported a first-quarter profit above analysts' estimates.
• Sara Lee Corp. (NYSE: SLE) Q3 profits surged but fell short of analysts' expectations.
• World Wrestling Entertainment Inc. (NYSE: WWE) posted strong results but couldn't cover its dividend.

Upcoming results to watch for include Sprint Nextel (NYSE: S), XM Satellite Radio (NASDAQ: XMSR), Sirius Satellite Radio (NASDAQ: SIRI), Electronic Arts (NASDAQ: ERTS), Whole Foods (NASDAQ: WFMI), Wal-Mart (NYSE: WMT), Deere & Co. (NYSE: DE), Toll Brothers (NYSE: TOL), Applied Materials (NASDAQ: AMAT), JC Penney (NYSE: JCP), Macy's (NYSE: M), Nordstrom (NYSE: JWN), Hewlett-Packard (NYSE: HPQ), Abercrombie & Fitch (NYSE: ANF).

Visit AOL Money & Finance for more earnings coverage.

eResearchTechnology (NASDAQ: ERES) provides technology and services to the pharmaceutical, biotechnology and medical device industries. The company streamlines the clinical trials process by enabling customers to automate the collection, analysis and distribution of data in all phases of clinical development. The firm's flagship product, EXPeRT, processes and interprets electrocardiogram data collected during trials, to insure cardiac safety. eResearchTechnology operates in the US and the UK.

The firm pleased investors earlier in the week, when it reported Q1 EPS of 11 cents and revenues of $33.7 million. Wall Street analysts had been looking for nine cents and $31.6 million. Management also guided Q2 EPS to 10-12 cents (ten cent Street), Q2 revenues to $34-$36 million ($32.95M Street), FY08 EPS to 44-49 cents (44 cent Street) and FY08 revenues to $133-$140 million ($134.99M Street). Friedman Billings subsequently reiterated its "outperform" rating on the shares and boosted its price target to $18.

eResearchTechnology (NASDAQ: ERES) provides technology and services to the pharmaceutical, biotechnology and medical device industries. The company streamlines the clinical trials process by enabling customers to automate the collection, analysis and distribution of data in all phases of clinical development. The firm's flagship product, EXPeRT, processes and interprets electrocardiogram data collected during trials, to insure cardiac safety. eResearchTechnology operates in the US and the UK.

The firm pleased investors late last month, when it reported Q4 EPS of ten cents and revenues of $28.9 million. Wall Street analysts had been looking for eight cents and $28.6 million. Management also guided Q1 EPS to 8-10 cents (nine cent Street view), Q1 revenues to $31-$33 million ($29.6M Street), FY08 EPS to 42-46 cents (41 cent Street) and FY08 revenues to $130-$137 million ($122.1M Street).